Compile Data Set for Download or QSAR
Report error Found 1339 Enz. Inhib. hit(s) with Target = 'Mitotic checkpoint serine/threonine-protein kinase BUB1'
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50076185(CHEMBL3416026 | US9290481, 1.1)
Affinity DataKd:  240nMAssay Description:Competitive binding affinity to human BUB1More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2016
Entry Details Article
PubMed
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378995(US10266548, Example 4-1 | Preparation of {3-[({2-[...)
Affinity DataIC50: 2.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415317(US10428044, Example 426 | Preparation of 3-{[2-(hy...)
Affinity DataIC50: 2.58nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378915(US10266548, Example 2-1-1 | 2-[1-(6-chloro-2-fluor...)
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378932(US10266548, Example 2-2-1 | 2-[1-(6-chloro-2- fluo...)
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379026(US10266548, Example 7-1 | Preparation of 1-[3,5-di...)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367598(US10227299, Example 288)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367317(Methyl (6RS)-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379006(US10266548, Example 4-2-1 | {3[({2-[1-(2- fluorobe...)
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379042(US10266548, Example 13-1 | Preparation of 2-({2-[1...)
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415374(US10428044, Example 487 | Preparation of 3-{[5-flu...)
Affinity DataIC50: 3.35nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379107(Preparation of 5-(2-aminoethoxy)-2-[1-(4-ethoxy-2,...)
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379108(2-[1-(4-ethoxy-2,6- difluorobenzyl)-1H- indazol-3-...)
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415373(US10428044, Example 486 | Preparation of 3-{[3-flu...)
Affinity DataIC50: 3.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415303(US10428044, Example 410 | Intermediate 1-2-69)
Affinity DataIC50: 3.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379024(US10266548, Example 6-1 | Preparation of 2-[1-(4-c...)
Affinity DataIC50: 3.90nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415283(US10428044, Example 390 | Preparation of 1-(1-meth...)
Affinity DataIC50: 3.96nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367593(US10227299, Example 283)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367367(US10227299, Example 61 | N-Methyl-4-oxo-3-(phenyla...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367368(US10227299, Example 60 | N,N-Dimethyl-4-oxo-3-(phe...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367372((6RS)-6-[(Ethylsulfanyl)methyl]-3-(phenylamino)-2-...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM395252(US10308629, Example 14 | (4aS,5aS or 4aR,5aR)-3-(P...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM395282(US10308629, Example 46 | N-{4-[[(4aR,5aR) or (4aS,...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM414909(US10428044, Example 7 | US10428044, Example 18 | U...)
Affinity DataIC50: 4.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415365(US10428044, Example 478 | Preparation of 1-benzyl-...)
Affinity DataIC50: 4.23nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415336(US10428044, Example 449 | Preparation of 1-benzyl-...)
Affinity DataIC50: 4.38nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378946(US10266548, Example 2-3-1 | 2-[1-(2-chloro- 4,5- d...)
Affinity DataIC50: 4.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415357(US10428044, Example 470 | Preparation of N-{4-[4&#...)
Affinity DataIC50: 4.49nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378960(US10266548, Example 2-4-1 | 2-[1-(2,6- difluoro-3-...)
Affinity DataIC50: 4.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415284(US10428044, Example 391 | Preparation of 1-{4-[6,6...)
Affinity DataIC50: 4.52nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378973(US10266548, Example 2-5-1 | 2-[1-(4-ethoxy- 2,6- d...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379040(US10266548, Example 12-2 | US10266548, Example 15-...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379040(US10266548, Example 12-2 | US10266548, Example 15-...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM415331(US10428044, Example 444 | 2-{[(2-aminopyridin-4-yl...)
Affinity DataIC50: 4.61nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM341151(US9765058, Example 2-1-1 | 4-({2-[4-chloro-5-cyclo...)
Affinity DataIC50: 4.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378980(US10266548, Example 2-6-1 | 2-[1-(2-chloro-4- meth...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378991(US10266548, Example 3-1 | Preparation of 2-[1-(4-e...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379045(4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM378982(US10266548, Example 2-7-1 | 2-[1-(2,6- difluoroben...)
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379041(US10266548, Example 12-3 | US10266548, Example 15-...)
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM379103(US10266548, Example 36-1 | US10266548, Example 36-...)
Affinity DataIC50: 4.91nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50011209(CHEMBL3260324)
Affinity DataIC50: 5nMAssay Description:Inhibition of Bub1 kinase (unknown origin) by TR-FRET kinase assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2015
Entry Details Article
PubMed
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367590(US10227299, Example 280)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367592(US10227299, Example 282)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367349((6RS)-6-Ethenyl-3-(phenylamino)-2-(pyridin-4-yl)-1...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367371((6RS)-3-(Phenylamino)-6-[(propan-2-ylsulfanyl)meth...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367412((6RS)—N-Methyl-N-(2-methylpropyl)-4-oxo-3-(ph...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367472(Methyl (6RS)-2-[3-(2-methoxyethoxy)pyridin-4-yl]-4...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM367507((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N,N...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM395255(US10308629, Example 17 | (4aR,5aR or 4aS,5aS)-5a-M...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1339 total ) | Next | Last >>
Jump to: